Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634232 | 0.89 | BCHE (0.60) | BCHEKDM4EMAPTKMT2AGAA | |
| Tetrahydropapaverine SCHEMBL29375914 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL30298903 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL30298880 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL1076975 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL6398843 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL31612469 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL30441145 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL251076 | 0.84 | BCHE (0.79) | BCHEKDM4EMAPTGAAHTT | |
| Tetrahydropapaverine SCHEMBL6382627 | 0.83 | BCHE (0.77) | BCHEKDM4EMAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100393703-C | 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-11 | — | — | CN | disclosed |
| CN-1288148-C | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-06 | — | — | CN | disclosed |
| EP-1379523-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-07-27 | — | — | EP | disclosed |
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| EP-1379523-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| CN-1416420-A | 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2003-05-07 | — | — | CN | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002076979-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-03 | — | — | WO | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | BCHE 831/4885KDM4E 2339/4885MAPT 1248/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | BCHE 2321/4885KDM4E 1711/4885MAPT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.